This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
BIIBNegative Net Change GILDNegative Net Change AXSMNegative Net Change PTGXNegative Net Change
biotechnology pharmaceuticals
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
SNYNegative Net Change AZNNegative Net Change BMYPositive Net Change NKTRNegative Net Change
biotechnology pharmaceuticals
Casey's General Stores (CASY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CASYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week
by Nalak Das
Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.
CVXPositive Net Change VNegative Net Change KOPositive Net Change MRKNegative Net Change AMGNNegative Net Change
biotechnology business-services consumer-staples pharmaceuticals
After Golden Cross, Ashland (ASH)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ASHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hoegh LNG (HMLP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
HMLPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Schnitzer Steel (SCHN) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SCHNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Texas Pacific (TPL)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TPLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
by Zacks Equity Research
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
BMYPositive Net Change EXELNegative Net Change VYGRPositive Net Change KLDOPositive Net Change
biotechnology biotechs pharmaceuticals
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
by Zacks Equity Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.
GSKNegative Net Change ALNYNegative Net Change HALONegative Net Change QUREPositive Net Change CRSPNegative Net Change
biotechnology pharmaceuticals
Top 5 High-Flying Nasdaq Stocks Amid Index's YTD Meltdown
by Nalak Das
We have narrowed our search to five Nasdaq listed stocks that have witnessed double-digit rally year to date. These are: VRTX, SPLK, HSIC, CHKP and JKHY.
CHKPNegative Net Change VRTXNegative Net Change HSICNegative Net Change JKHYNegative Net Change SPLKPositive Net Change
biotechnology medical
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
BMYPositive Net Change MRKNegative Net Change VYGRPositive Net Change VTGNNegative Net Change
biotechnology biotechs pharmaceuticals
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change VTGNNegative Net Change
biotechnology pharmaceuticals
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change NTLANegative Net Change
biotechnology biotechs pharmaceuticals
Antibody Treatments for COVD-19 Face Challenges in the U.S.
by Ekta Bagri
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.
REGNNegative Net Change AZNNegative Net Change GSKNegative Net Change LLYPositive Net Change VIRNegative Net Change
biotechnology pharmaceuticals
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
REGNNegative Net Change BMYPositive Net Change
biotechnology cancer cell-therapy coronavirus earnings genetics hospitals immuno-therapy investing large-cap medical medical-devices pharmaceuticals
Chefs' Warehouse (CHEF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CHEFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
VIR Stock Down on Another Setback for COVID-19 Antibody
by Zacks Equity Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
REGNNegative Net Change GSKNegative Net Change LLYPositive Net Change VIRNegative Net Change
biotechnology pharmaceuticals
Graphic Packaging (GPK) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GPKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Perion Network (PERI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PERIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
BMYPositive Net Change MRKNegative Net Change VYGRPositive Net Change VTGNNegative Net Change
biotechnology medical
Should You Buy Piedmont Lithium Inc. (PLL) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, YPF Sociedad Anonima (YPF)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
YPFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Wex (WEX)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
WEXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Apr 5, 2022
by Zacks Equity Research
Companies in the News Are: PDD,ROKU,SBUX,MRNA,AMZN
AMZNNegative Net Change SBUXNegative Net Change MRNANegative Net Change ROKUNegative Net Change PDDNegative Net Change
biotechnology consumer-discretionary internet medical retail tech-stocks